A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

• Currently, Proton Pump Inhibitors and H2Receptor Blockers are widely used by emergency physicians in Turkey for the treatment of patients with dyspepsia.

• The objective of the study was to assess whether intravenous esomeprazol has superior dyspeptic pain reduction compared with ranitidine or hydrotalcid in emergency department (ED) adults

• The investigators second aim was to compare recurrent dyspeptic pain within 24 hours after discharge and cost of treatments in the treatment of dyspepsia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pamukkale University
• Treatments: Esomeprazole; Ranitidine; Ranitidine bismuth citrate

Criteria

Inclusion Criteria:

• patients were eligible for inclusion if they were aged 18 years or older, 60 years or older,

• had dyspspsia [VAS (visual analog scale) score >5] during their ED episode of care for which the attending physician recommended medication.

Exclusion Criteria:

• pretreatment 100-mm linear visual analog scale (VAS) pain score less than 50 mm;

• known cases of malignancy or terminal illness;

• known cases of major medical problems (eg, any evidence of active structural or functional abnormality of the hearts, chronic renal failure)

• allergy or previous adverse reaction to study drugs studied

• received agents to inhibit the secretion of acid (PPIs or histamine-2 receptor antagonists), nonsteroidal anti-inflammatory drugs,

• who consumed alcohol within 4 hours before the ED visit

• diarrhea more than 2 times within the past 24 hours;

• being suspected to have other ED diagnoses (eg, gut obstruction, biliary colic, pancreatitis, hepatitis, or localized hepatobiliary infections);

• being pregnant or breast-feeding; and

• inability to comprehend the VAS evaluation.

• and patients who refused to participate study.